Skip to main content
Clinical Trials/NCT02056145
NCT02056145
Unknown
Not Applicable

Ultrasound Guided Lateral Femoral Cutaneous Block (LFCNB) And Femoral Nerve Block (FNB) For Postoperative Pain Control After Hip Surgery

University Hospital, Antwerp1 site in 1 country210 target enrollmentOctober 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
-Postoperative Pain
Sponsor
University Hospital, Antwerp
Enrollment
210
Locations
1
Primary Endpoint
Use of opioids
Last Updated
11 years ago

Overview

Brief Summary

Evaluation of the combination of lateral femoral cutaneous nerve "single shot" and femoral nerve "single shot" block as effective and safe alternative postoperative analgesic technique after hip replacement surgery.

Detailed Description

Clinical evaluation via a prospective, double-blinded, randomized clinical trial, whether ultrasound-guided single femoral block and lateral femoral cutaneous nerve blocks with 20 en 10 cc bupivacaine 0.25% respectively vs. the only ultrasound-guided single femoral block with 20 cc bupivacaine 0.25%, given just prior to elective hip surgery procedure, is effective in reducing acute postoperative pain (VAS scores) and postoperative opiate consumption.

Registry
clinicaltrials.gov
Start Date
October 2011
End Date
August 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ethisch Comité UZ Antwerpen

Ethische Comité UZ Antwerpen

University Hospital, Antwerp

Eligibility Criteria

Inclusion Criteria

  • Primary hip arthroplasty with posterolateral approach.

Exclusion Criteria

  • Known allergy to levobupivacaine and / or piritramide
  • Known neurological disorders or peripheral neuropathies
  • Existing drug or alcohol abuse
  • Chronic use of pain medication (\> started 3 months ago) not related to the hip suffering
  • Coagulopathy (international normalized ratio) \> 1.4
  • Thrombocytopenia \<70,000 platelets,
  • Pregnancy
  • Local infection hip
  • Hepatic and / or renal impairment
  • BMI\> 45.

Outcomes

Primary Outcomes

Use of opioids

Time Frame: 48 hours

The primary outcome measure will be a consumption of opioids through the Intravenous Patient Controlled Analgesia pump. Those amounts will be measured en documented at the fixed intervals during the first 48 hours post-procedure.

Secondary Outcomes

  • Visual analog scale (VAS) scores (0-10)(48 hours)

Study Sites (1)

Loading locations...

Similar Trials